These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35553024)

  • 1. Anti-complement Agents for Autoimmune Neurological Disease.
    McCombe JA; Pittock SJ
    Neurotherapeutics; 2022 Apr; 19(3):711-728. PubMed ID: 35553024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoreactive T and B cells in nervous system diseases.
    Sun JB
    Acta Neurol Scand Suppl; 1993; 142():1-56. PubMed ID: 8382894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement and myasthenia gravis.
    Sanderson NSR
    Mol Immunol; 2022 Nov; 151():11-18. PubMed ID: 36063582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myasthenia gravis, a model of organ-specific autoimmune disease.
    Berrih-Aknin S
    J Autoimmun; 1995 Apr; 8(2):139-43. PubMed ID: 7612144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
    Beecher G; Putko BN; Wagner AN; Siddiqi ZA
    Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities.
    Rose N; Holdermann S; Callegari I; Kim H; Fruh I; Kappos L; Kuhle J; Müller M; Sanderson NSR; Derfuss T
    Acta Neuropathol; 2022 Nov; 144(5):1005-1025. PubMed ID: 36074148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
    Fichtner ML; Jiang R; Bourke A; Nowak RJ; O'Connor KC
    Front Immunol; 2020; 11():776. PubMed ID: 32547535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis.
    Nakata R; Motomura M; Masuda T; Shiraishi H; Tokuda M; Fukuda T; Ando T; Yoshimura T; Tsujihata M; Kawakami A
    Eur J Neurol; 2013 Sep; 20(9):1272-6. PubMed ID: 23679930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder.
    Dodig D; Genge A; Selchen D; Freedman MS
    Can J Neurol Sci; 2023 Mar; 50(2):165-173. PubMed ID: 34895385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disorders affecting the acetylcholine receptor: myasthenia gravis and congenital myasthenia.
    Vincent A
    J Recept Res; 1987; 7(1-4):599-616. PubMed ID: 2442386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies.
    Ozawa Y; Uzawa A; Onishi Y; Yasuda M; Kojima Y; Kuwabara S
    Muscle Nerve; 2023 Nov; 68(5):798-804. PubMed ID: 37705312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.
    Chamberlain JL; Huda S; Whittam DH; Matiello M; Morgan BP; Jacob A
    J Neurol; 2021 May; 268(5):1643-1664. PubMed ID: 31482201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis.
    Aharonov A; Abramsky O; Tarrab-Hazdai R; Fuchs S
    Lancet; 1975 Aug; 2(7930):340-2. PubMed ID: 51144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.
    Fichtner ML; Hoarty MD; Vadysirisack DD; Munro-Sheldon B; Nowak RJ; O'Connor KC
    PLoS One; 2022; 17(3):e0264489. PubMed ID: 35290370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis.
    Stascheit F; Chuquisana O; Keller CW; Ambrose PA; Hoffmann S; Gross CC; Lehnerer S; Wiendl H; Willcox N; Meisel A; Lünemann JD
    Eur J Neurol; 2023 May; 30(5):1409-1416. PubMed ID: 36752022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunopathology of myasthenia gravis.
    Lennon VA
    Hum Pathol; 1978 Sep; 9(5):541-51. PubMed ID: 309428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenia gravis as a prototype autoimmune receptor disease.
    Hoedemaekers AC; van Breda Vriesman PJ; De Baets MH
    Immunol Res; 1997; 16(4):341-54. PubMed ID: 9439759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.